Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

Inclusion Criteria: * Male or female outpatients aged ≥7 to \<18 years (at Screening Visit 1). * Provide assent (subject) and written informed consent (parent/legal representative) and Health Insurance Portability and Accountability Act (HIPAA) for study participation (at Screening Visit 1). * Meet diagnostic criteria for MDD as defined in the DSM IV-TR5 at Screening Visits 1 and 1a (K-SADS-PL; see Appendix 17.2). * Current depressive episode of at least 4 weeks' duration as noted in the subject's history (Screening Visit 1). * Total CDRS-R raw score ≥45 at both the Screening and Baseline Visits (Visits 1 and 2) (see Appendix 17.3). * CGI-S score of ≥4 at the Baseline Visit (Visit 2) (see Appendix 17.4). Exclusion Criteria: * are unable to swallow medications without difficulty * have known hypersensitivity to bupropion hydrobromide * are pregnant or planning to get pregnant or are lactating * Women of childbearing age unable to use at least one method of effective contraception for the duration of the study * Previous history of attempted suicide * are unable to understand and communicate effectively with parent, Investigator, and study coordinator * are at immediate risk of requiring hospitalization, in the Investigator's opinion * have current seizure disorder or history of seizures or head trauma * have history or presence of clinically significant medical conditions or clinically important laboratory abnormalities * have ECG or physical examination abnormality at screening * have body weight less than the 3rd percentile or greater than the 97th percentile for age.